

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 7933-38		SERIAL NO. 09/744,409	
INFORMATION DISCLOSURE CITATION				APPLICANT: MICHAEL S. HALPERN et al.			
				FILING DATE January 22, 2001			
				GROUP 1633 1642			



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	4,673,563	06/1987	Berne et al.	424	9	
	AB	5,593,972	01/1997	Weiner et al.	514	44	
	AC	5,656,481	08/1997	Baetge et al.	435	325	
	AD	5,693,522	12/1997	Chada et al.	435	325	
	AE	09/167,322		Halpern et al.			10/7/1998

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AF	0 119 702	09/1984	Europe				
	AG	WO 92/14756	09/1992	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AH	Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure", <i>Proc. Natl. Acad. Sci. USA</i> , 84: 7413-7417, November 1987
	AI	Kuzumaki et al., "Transplantation Resistance to a Rous Sarcoma Virus-Induced Tumor in Mice Immunized With v-src Protein", <i>J. Natl. Cancer Inst.</i> , Vol 80, No. 12, August 17, 1988, pp 959-962
	AJ	Fendly et al., "The Extracellular Domain of HER2/neu Is a potential Immunogen for Active Specific Immunotherapy of Breast Cancer", <i>J. Biol. Response Mod.</i> , Vol. 9, No. 5, October 1990, pp 449-455
	AK	Malone et al., "Cationic liposome-mediated RNA transfection", <i>Proc. Natl. Acad. Sci. USA</i> , 86: 6077-6081, August 1989
	AL	Temin, "Overview of biological effects of addition of DNA molecules to cells", <i>J. Med. Virol.</i> , 31:13-17, May 1990
	AM	Wisner et al., Tumor Immunity Generated in the Course of Regression of v-src-Induced Sarcomas", <i>J. Virol.</i> , Vol. 65(12):7020-7024, December 1991
	AN	Halpern et al., "Immune-Based Resistance to the Formation of v-src-Induced Distal Tumors", <i>Virology</i> 197:480-484, 1993
	AO	Disis et al., "In Vitro Generation of Human Cytolytic T-Cells Specific for Peptides Derived From the HER-2/neu Protooncogene Protein", <i>Cancer Research</i> , 54:1071-1076, February 15, 1994


EXAMINER 	DATE CONSIDERED 3/24/02
--------------	----------------------------

EXAMER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
7933-38SERIAL NO.
09/744,406

INFORMATION DISCLOSURE CITATION



APPLICANT:

MICHAEL S. HALPERN et al.

FILING DATE

January 22, 2001

GROUP 1633

1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Taylor <i>et al.</i> , "Major Histocompatibility (B) Complex Control of the Formation of v-src-Induced Metastases", <u>Virology</u> , 205:569-573, 1994
AQ	Plachý <i>et al.</i> "src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors", <u>Immunogenetics</u> , 40:257-265, 1994
AR	Peoples <i>et al.</i> , "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide", <u>Proc. Natl. Acad. Sci., USA</u> , 92:432-436, January 1995
AS	Conry <i>et al.</i> , "Characterization of a Messenger RNA Polynucleotide Vaccine Vector", <u>Cancer Res.</u> , Vol. 55:1397-1400, 1 April 1995
AT	McCabe <i>et al.</i> , "Minimal Determinant Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic Antitumor Cytolytic T Lymphocyte Responses", <u>Cancer Research</u> , 55:1741-1747, April 15, 1995
AU	Fenton <i>et al.</i> "Cytotoxic T-cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes", <u>J. Natl. Cancer Inst.</u> , 85(16):1294-1302, August 18, 1993
AV	Halpern <i>et al.</i> "Endogenous c-src as a determinant of the tumorigenicity of src oncogenes", <u>Proc. Natl. Acad. Sci., USA</u> , 93:824-827, January 23, 1996
AW	Disis <i>et al.</i> , "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer", <u>Cancer Research</u> 54:16-20, January 1, 1994
AX	Gelman <i>et al.</i> , "Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains", <u>Oncogene</u> , 8:2995-3004, 1993
AY	Gilbert <i>et al.</i> , "Tolerogenicity of Resting and Activated B Cells", <u>J. Exp. Med.</u> , 179:249-258, 1994
AZ	Fuchs <i>et al.</i> , "B Cells Turn Off Virgin But Not Memory T Cells", <u>Science</u> , 258:1156-1159, 1992
BA	Verma <i>et al.</i> , "Gene therapy - promises, problems and prospects" <u>Nature</u> , 389: 239-242, 1997
BB	Restifo <i>et al.</i> , "Molecular Mechanisms Used by Tumors to Escape Immune Recognition: Immunogenetherapy and the Cell Biology of Major Histocompatibility Complex Class I", <u>J. Immunother.</u> , Vol. 14, 182-190 (1993)
BC	Yasutomi <i>et al.</i> , "A Vaccine-Elicited, Single Viral Epitope-Specific Cytotoxic T Lymphocyte Response Does Not Protect against Intravenous, Cell-Free Simian Immunodeficiency Virus Challenge", <u>J. Virol.</u> , Vol. 69 No. 4 (April 1995), 2279-2284
BD	Marshall, Gene Therapy's Growing Pains, <u>Science</u> . 269:1050-1055, 25 August 1995
BE	Orkin <i>et al.</i> , Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995

EXAMINER

DATE CONSIDERED

3/24/02

EXAM: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line thru citation if in conformance and not considered. Include copy of this form with next communication to applicant.

PHIP/301014/1

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
7933-38SERIAL NO.
09/744,406

INFORMATION DISCLOSURE CITATION

APPLICANT:
MICHAEL S. HALPERN et al.FILING DATE
January 22, 2001

GROUP 1633

1642

TECH CENTER 16012900

JUL 11 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BF	Friedmann, Overcoming the Obstacles to Gene Therapy, <i>Scientific American</i> , June 1997, 96-101
BG	Huang <i>et al.</i> , "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens", <i>Science</i> , 264:961-965, 13 May 1994
BH	Céfaï <i>et al.</i> , "Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer", <i>Int. J. Cancer</i> , 83:393-400, 1999

EXAMINER

DATE CONSIDERED

3/24/02

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line
 10
 formance and not considered. Include copy of this form with next communication to applicant.
 91014/1